Literature DB >> 34028522

The physiological role of estrogen receptor functional domains.

Yukitomo Arao1, Kenneth S Korach1.   

Abstract

Estrogen receptor (ER) is a member of the nuclear receptor superfamily whose members share conserved domain structures, including a DNA-binding domain (DBD) and ligand-binding domain (LBD). Estrogenic chemicals work as ligands for activation or repression of ER-mediated transcriptional activity derived from two transactivation domains: AF-1 and AF-2. AF-2 is localized in the LBD, and helix 12 of the LBD is essential for controlling AF-2 functionality. The positioning of helix 12 defines the ER alpha (ERα) ligand properties as agonists or antagonists. In contrast, it is still less well defined as to the ligand-dependent regulation of N-terminal AF-1 activity. It has been thought that the action of selective estrogen receptor modulators (SERMs) is mediated by the regulation of a tissue specific AF-1 activity rather than AF-2 activity. However, it is still unclear how SERMs regulate AF-1 activity in a tissue-selective manner. This review presents some recent observations toward information of ERα mediated SERM actions related to the ERα domain functionality, focusing on the following topics. (1) The F-domain, which is connected to helix 12, controls 4-hydroxytamoxifen (4OHT) mediated AF-1 activation associated with the receptor dimerization activity. (2) The zinc-finger property of the DBD for genomic sequence recognition. (3) The novel estrogen responsive genomic DNA element, which contains multiple long-spaced direct-repeats without a palindromic ERE sequence, is differentially recognized by 4OHT and E2 ligand bound ERα transactivation complexes.
© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  DNA binding domain; estrogen receptor; estrogen responsive element; ligand binding domain; selective estrogen receptor modulators; transactivation

Mesh:

Substances:

Year:  2021        PMID: 34028522      PMCID: PMC8611119          DOI: 10.1042/EBC20200167

Source DB:  PubMed          Journal:  Essays Biochem        ISSN: 0071-1365            Impact factor:   8.000


  56 in total

Review 1.  Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications.

Authors:  W Bourguet; P Germain; H Gronemeyer
Journal:  Trends Pharmacol Sci       Date:  2000-10       Impact factor: 14.819

Review 2.  Principles for modulation of the nuclear receptor superfamily.

Authors:  Hinrich Gronemeyer; Jan-Ake Gustafsson; Vincent Laudet
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

Review 3.  Looking at nuclear receptors from a new angle.

Authors:  Christine Helsen; Frank Claessens
Journal:  Mol Cell Endocrinol       Date:  2013-09-18       Impact factor: 4.102

4.  The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands.

Authors:  R M Blair; H Fang; W S Branham; B S Hass; S L Dial; C L Moland; W Tong; L Shi; R Perkins; D M Sheehan
Journal:  Toxicol Sci       Date:  2000-03       Impact factor: 4.849

5.  Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein.

Authors:  K E Weis; K Ekena; J A Thomas; G Lazennec; B S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  1996-11

6.  Nonclassical estrogen receptor alpha signaling mediates negative feedback in the female mouse reproductive axis.

Authors:  C Glidewell-Kenney; L A Hurley; L Pfaff; J Weiss; J E Levine; J L Jameson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 7.  Estrogen receptor mutations in breast cancer.

Authors:  S A Fuqua; G C Chamness; W L McGuire
Journal:  J Cell Biochem       Date:  1993-02       Impact factor: 4.429

8.  Estrogen receptor α L543A,L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity.

Authors:  Yukitomo Arao; Katherine J Hamilton; Laurel A Coons; Kenneth S Korach
Journal:  J Biol Chem       Date:  2013-06-03       Impact factor: 5.157

9.  Retinoic acid inhibits estrogen-induced uterine stromal and myometrial cell proliferation.

Authors:  H L Boettger-Tong; G M Stancel
Journal:  Endocrinology       Date:  1995-07       Impact factor: 4.736

10.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

View more
  5 in total

Review 1.  ERK1/2-RSK regulation of oestrogen homeostasis.

Authors:  Eric B Wright; Deborah A Lannigan
Journal:  FEBS J       Date:  2022-02-17       Impact factor: 5.622

2.  Nuclear receptors: from molecular mechanisms to therapeutics.

Authors:  Daniel E Frigo; Maria Bondesson; Cecilia Williams
Journal:  Essays Biochem       Date:  2021-12-17       Impact factor: 8.000

3.  Effect of Hysteroscopic Polypectomy Combined with Mirena Placement on Postoperative Adverse Reactions and Recurrence Rate of Endometrial Polyps: Based on a Large-Sample, Single-Center, Retrospective Cohort Study.

Authors:  Yanli Shen; Wenguang Feng; Jing Yang; Jinling Yi
Journal:  Biomed Res Int       Date:  2022-04-26       Impact factor: 3.246

Review 4.  The Isoforms of Estrogen Receptor Alpha and Beta in Thyroid Cancer.

Authors:  Zhongqin Gong; Shucai Yang; Minghui Wei; Alexander C Vlantis; Jason Y K Chan; C Andrew van Hasselt; Dongcai Li; Xianhai Zeng; Lingbin Xue; Michael C F Tong; George G Chen
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

5.  Metabolic Syndrome, BMI, and Polymorphism of Estrogen Receptor-α in Peri- and Post-Menopausal Polish Women.

Authors:  Jan Krakowiak; Dorota Raczkiewicz; Ewa Humeniuk; Artur Wdowiak; Andrzej Wróbel; Iwona Bojar
Journal:  Metabolites       Date:  2022-07-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.